In the cardio-oncology population, drug interactions are of particular importance given the
complex pharmacological profile, narrow therapeutic index, and inherent risk of therapies …

Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …

Asparaginase is an integral component of multiagent chemotherapy regimens for the
treatment of children with acute lymphoblastic leukemia. Positive outcomes are seen in …

Although there are high survival rates for children with acute lymphoblastic leukaemia, their
outcome is often counterbalanced by the burden of toxic effects. This is because reported …

Background l-asparaginase is a universal component of treatment for childhood acute
lymphoblastic leukaemia, and is usually administered intramuscularly. Pegylated …

Pediatric Acute Lymphoblastic Leukemia (ALL) cure rates have improved exponentially over
the past five decades with now over 90% of children achieving long-term survival. A direct …

The rapidly increasing use of pegasparaginase (pegASNase) in adults, after a half century
of use of asparaginase (ASNase) in children, has prompted a need for guidelines in the …

While the majority of children and adolescents with newly diagnosed childhood acute
lymphoblastic leukemia (ALL) will be cured, as many as 20% of patients will experience …

Venous thromboembolism (VTE) remains a major cause of morbidity and mortality in
patients with cancer. Although some very well validated scores delineate the risk of VTE by …

The association between malignancy and thrombosis has been recognized for over a
century and a half. Patients with cancer have an elevated risk of both initial and recurrent …